Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 9/20 | 0.66 |
| ▸ | TNF | P01375 | 6/20 | 0.66 |
| ▸ | IL1B | P01584 | 4/20 | 0.66 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.66 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.61 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19611900 | 0.93 | CRBN (0.58) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19611901 | 0.93 | CRBN (0.58) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24671340 | 0.92 | CRBN (0.64) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2030317 | 0.92 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL3543582 | 0.92 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2032185 | 0.92 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL31628528 | 0.91 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25568961 | 0.91 | CRBN (0.62) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL26317801 | 0.90 | CRBN (0.69) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL25233562 | 0.87 | CRBN (0.72) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-113412259-A | Bifunctional compounds for the degradation of BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-3862348-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-08-11 | — | — | EP | disclosed |
| US-20210220391-A1 | PROTEOLYSIS TARGETING CHIMERIC MOLECULES (PROTACS) WITH FUNCTIONAL HANDLES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-7820697-B2 | Compositions and method for reducing TNFα levels | CELGENE CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2008-11-20 | — | — | US | disclosed |
| US-20060030592-A1 | I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2006-02-09 | — | — | US | disclosed |
| EP-1064277-B1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | CELGENE CORP (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1357120-A1 | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORPORATION (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2003-02-06 | — | — | US | disclosed |
| US-6403613-B1 | ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) | CELGENE CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | MAN HON-WAH (US) | 2001-07-05 | — | — | US | disclosed |
| EP-1064277-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | Gelgene Corporation (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047512-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | COLGENE CORPORATION (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030592-A1 | I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | IL1A, IL1B, TNF | CRBN 4100/4885IKZF3 97/4885TNF 3/4885 |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | IL1A, IL1B, TNF | CRBN 4056/4885IKZF3 275/4885TNF 3/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | CRBN 65/4885IKZF3 282/4885TNF 4118/4885 |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | TNF, IL1A, IL1B | CRBN 4134/4885IKZF3 275/4885TNF 1/4885 |
| US-20210220391-A1 | PROTEOLYSIS TARGETING CHIMERIC MOLECULES (PROTACS) WITH FUNCTIONAL HANDLES AND USES THEREOF | CRBN, PSMA6, PSMA3 | CRBN 1/4885IKZF3 832/4885TNF 2734/4885 |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | TNF, IL1A, IL1B | CRBN 4134/4885IKZF3 275/4885TNF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.